The challenge of managing fusariosis

Figures & data

Table 1 Minimum inhibitory concentration (MIC) for Fusarium isolates treated with amphotericin B, voriconazole, and posaconazole.

						MIC µg/ mL
		amphotericin B			voriconazole			posaconazole			References
Fusarium species	Number of samples	50%	Range	90%	50%	Range	90%	50%	Range	90%
F. solani	32	1	N/A	2	>8	N/A	>8	>8	N/A	>8	76
	2	N/A	4	1	N/A	>8	N/A	1	1	N/A	77
	22	N/A	0.5 to 8	1.33	N/A	4 to 16	14	N/A	16	16	21
	13	2	0.5 to 4	4	8	1 to 16	16	N/A	N/A	N/A	20
	19	1.25	N/A	N/A	9.21	N/A	N/A	15.21	N/A	N/A	18
	15	N/A	1 to 16	N/A	N/A	4 to 16	N/A	N/A	N/A	N/A	22
F. oxysporum	17	1	N/A	2	4	N/A	>8	4	N/A	>8	76
	2	N/A	1 to 4	2.5	N/A	4>8	N/A	0.12	0.125	N/A	77
	14	N/A	0.12 to 2	0.78	N/A	0.5 to 16	4	N/A	0.06 to 16	4.63	21
	9	2.3	N/A	N/A	4	N/A	N/A	2.7	N/A	N/A	18
	7	N/A	1 to >16	N/A	N/A	2 to 16	N/A	N/A	N/A	N/A	22
species not specified	67	8	N/A	32	16	N/A	32	16	N/A	32	14
	20	N/A	N/A	N/A	4	1 >16	16	N/A	N/A	N/A	19
	3	N/A	2 to 4	N/A	N/A	2 to 8	N/A	N/A	N/A	N/A	20

N/A, not applicable

Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Monzon A, Buitrago MJ, Rodriguez-Tudela JL. Activity profile in vyitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. Antimicrob Agents Chemother 2009; 53:2192 - 2195

 PubMed Web of Science ®Google Scholar

Lass-Florl C, Mayr A, Perkhofer S, Hinterberger G, Hausdorfer J, Speth C, et al. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2008; 52:3637 - 3641

 PubMed Web of Science ®Google Scholar

Alastruey-Izquierdo A, Cuenca-Estrella M, Monzon A, Mellado E, Rodriguez-Tudela JL. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother 2008; 61:805 - 809

 PubMed Web of Science ®Google Scholar

Espinel-Ingroff A, Johnson E, Hockey H, Troke P. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother 2008; 61:616 - 620

 PubMed Web of Science ®Google Scholar

Tortorano AM, Prigitano A, Dho G, Esposto MC, Gianni C, Grancini A, et al. Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. Antimicrob Agents Chemother 2008; 52:2683 - 2685

 PubMed Web of Science ®Google Scholar

Cordoba S, Rodero L, Vivot W, Abrantes R, Davel G, Vitale RG. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int J Antimicrob Agents 2008; 31:171 - 174

 PubMed Web of Science ®Google Scholar

Cornely OA. Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection 2008; 36:296 - 313

 PubMed Web of Science ®Google Scholar

Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008; 52:1396 - 1400

 PubMed Web of Science ®Google Scholar